Zevra Therapeutics Inc. (ZVRA), a commercial-stage company developing treatments for rare diseases, has announced financial results for the fourth quarter and full year that ended Dec.31, 2024.
The company's marketed drugs include OLPRUVA for the treatment of Urea Cycle Disorders, recently approved MIPLYFFA for the treatment of Niemann Pick disease type C, and *AZSTARYS for the treatment of Attention Deficit and Hyperactivity Disorder. *AZSTARYS is a partnered program with Commave Therapeutics.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com